XOMA Corp
NASDAQ:XOMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
XOMA Corp
Interest Income Expense
XOMA Corp
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XOMA Corp
NASDAQ:XOMA
|
Interest Income Expense
-$5.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$224m
|
CAGR 3-Years
48%
|
CAGR 5-Years
39%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$732m
|
CAGR 3-Years
20%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$466.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
XOMA Corp
Glance View
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
See Also
What is XOMA Corp's Interest Income Expense?
Interest Income Expense
-5.8m
USD
Based on the financial report for Dec 31, 2025, XOMA Corp's Interest Income Expense amounts to -5.8m USD.
What is XOMA Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-4%
